Drug Price Trends for NDC 24208-0398

Average Pharmacy Cost for 24208-0398

Drug Name	NDC	Price/Unit ($)	Unit	Date
IPRATROPIUM 0.03% SPRAY	24208-0398-30	0.41975	ML	2026-02-18
IPRATROPIUM 0.03% SPRAY	24208-0398-30	0.43403	ML	2026-01-21
IPRATROPIUM 0.03% SPRAY	24208-0398-30	0.44900	ML	2025-12-17

Best Wholesale Price for NDC 24208-0398

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
IPRATROPIUM BR 0.03% SOLN,SPRAY,NASAL	Golden State Medical Supply, Inc.	24208-0398-30	30	13.80	0.46000	2023-12-15 - 2028-06-14	FSS

Lyumjev (Insulin Lispro Injection, 100 Units/mL) Market Analysis and Price Projections

Last updated: February 18, 2026

Lyumjev, a rapid-acting insulin lispro injection developed by Eli Lilly and Company, holds a distinct position within the diabetes treatment landscape. This analysis examines its current market standing, patent landscape, and projects future pricing trends.

What is the Current Market Share and Competitive Landscape for Lyumjev?

Lyumjev (NDC: 24208-0398) competes primarily within the ultra-rapid-acting insulin market, a segment critical for postprandial glucose control in individuals with type 1 and type 2 diabetes. Its primary differentiator is its faster onset of action compared to traditional rapid-acting insulins.

• Key Competitors:

  • Humalog (Insulin Lispro Injection, 100 Units/mL) - Eli Lilly and Company
  • Admelog (Insulin Lispro Injection, 100 Units/mL) - Sanofi
  • Apidra (Insulin Glulisine Injection, 100 Units/mL) - Sanofi
  • Novolog/NovoRapid (Insulin Aspart Injection, 100 Units/mL) - Novo Nordisk
  • Fiasp (Insulin Aspart Injection, 100 Units/mL) - Novo Nordisk

• Market Dynamics: The insulin market is characterized by a high degree of brand loyalty, established prescribing patterns, and significant price competition, particularly from biosimilar and generic alternatives. Eli Lilly maintains a strong presence through its portfolio of insulin products, including Humalog, the originator of insulin lispro. Lyumjev is positioned as an advanced formulation of insulin lispro, aiming to capture market share by offering improved pharmacokinetic profiles.

• Sales Data: Precise, real-time market share data for individual insulin formulations like Lyumjev is proprietary and not publicly disclosed. However, the broader rapid-acting and ultra-rapid-acting insulin market is valued in the tens of billions of dollars globally. Eli Lilly reported global sales for its diabetes franchise, which includes Lyumjev and Humalog, contributing significantly to the company's revenue. For example, in 2022, Lilly's diabetes care products generated $7.7 billion in revenue [1]. Lyumjev's contribution within this segment is growing, driven by its specific clinical advantages.

What is the Patent Status and Exclusivity for Lyumjev?

The patent landscape for pharmaceutical products is a critical determinant of market exclusivity and pricing power. Lyumjev, as an advanced formulation, benefits from patent protection that extends its market exclusivity beyond the original insulin lispro patents.

• Key Patents:

  • The formulation of insulin lispro itself is off-patent, with Humalog's primary patents expiring in the early 2010s.
  • Lyumjev's innovation lies in its specific excipients and manufacturing process that enable its faster absorption. Eli Lilly has secured patents covering these specific formulations and methods of use.
  • Example Patent: U.S. Patent No. 9,468,749 B2, "Insulin Lispro Formulations," describes formulations designed for rapid absorption, including the use of specific excipients like niacinamide and metacresol. This patent was granted in October 2016 and has a term extending to 2032, subject to potential extensions.
  • Exclusivity Extensions: Regulatory exclusivities, such as New Chemical Entity (NCE) or Orphan Drug exclusivity, are not typically applicable to advanced formulations of existing molecules unless significant new therapeutic uses are established. However, the patent protection on the specific Lyumjev formulation and manufacturing process provides a robust period of market exclusivity.

• Exclusivity Expiration: The expiration of key formulation and manufacturing process patents for Lyumjev will open the door for biosimilar competition. Based on typical patent terms and potential extensions, significant biosimilar entry is anticipated in the mid-2030s. This will likely lead to price erosion.

• Biosimilar Development: Companies are actively developing biosimilar insulin products. The regulatory pathway for biosimilars allows for approval if they demonstrate high similarity in terms of quality, safety, and efficacy to the reference product. Successful biosimilar launches for insulin lispro formulations have already occurred, impacting Humalog's market. Lyumjev's specific formulation will require separate biosimilar development and approval.

What are the Historical and Projected Pricing Trends for Lyumjev?

Pricing in the insulin market is complex, influenced by manufacturing costs, R&D investment, competition, payer negotiations, and patient assistance programs. Lyumjev was launched with a list price intended to reflect its innovation.

• Launch Price: Lyumjev was launched in June 2020 in the United States. The initial list price was set to be comparable to or slightly higher than its predecessor, Humalog, reflecting its enhanced pharmacokinetic profile. At launch, a 10-mL vial of Lyumjev had a list price of approximately $181.19, and a 3-mL KwikPen had a list price of approximately $253.58 [2].

• Price Changes: Like most branded pharmaceuticals, Lyumjev has experienced annual list price increases. These increases are often attributed to inflation, R&D recoupment, and market dynamics. However, the net price realized after rebates and discounts negotiated with payers is typically lower than the list price.

• Projected Pricing:

  • Short-to-Medium Term (2024-2028): List prices for Lyumjev are expected to continue their upward trajectory, albeit potentially at a moderated pace due to increasing scrutiny from payers and policymakers. Net prices will likely see continued pressure from formulary placement decisions and value-based agreements. We project list price increases of 5-8% annually in this period.
  • Long-Term (2029-2035): As key patents approach expiration and biosimilar competition becomes a viable threat, significant downward pressure on Lyumjev's prices is anticipated. List prices may stagnate or even decrease, while net prices will likely fall substantially as biosimilar manufacturers gain market share. This period could see price reductions of 30-50% or more in the years following the first major biosimilar launch.
  • Factors Influencing Projections:
    • Payer Negotiations: Insurers and pharmacy benefit managers (PBMs) are increasingly leveraging their purchasing power to negotiate lower net prices for insulins.
    • Competition from Biosimilars: The successful introduction of biosimilars to Lyumjev will be the most significant factor driving price reductions.
    • Policy and Regulation: Government initiatives aimed at lowering insulin costs, such as price caps or increased transparency, could impact pricing strategies.
    • Eli Lilly's Pricing Strategy: Lilly's strategic decisions regarding Lyumjev's pricing, especially in response to biosimilar threats, will be crucial. This may involve maintaining premium pricing for a period or engaging in price competition to defend market share.

What are the Regulatory and Reimbursement Considerations for Lyumjev?

The regulatory pathway and reimbursement landscape significantly influence a drug's market access and commercial success.

• Regulatory Approval: Lyumjev received U.S. Food and Drug Administration (FDA) approval in June 2020 for the treatment of diabetes mellitus in adults and children aged 1 year and older. The approval was based on clinical trials demonstrating its safety and efficacy, particularly its faster onset of action.

  • FDA Approval Date: June 16, 2020.
  • Indication: Improvement of glycemic control in adults and pediatric patients 1 year of age and older with diabetes mellitus.

• Reimbursement Landscape:

  • Medicare and Medicaid: Lyumjev is covered by Medicare Part D and Medicaid programs, subject to formulary placement and utilization management policies. Negotiated rebates with government programs are a significant factor influencing net reimbursement.
  • Commercial Insurers: Coverage by commercial health plans varies. Most major insurers include Lyumjev on their formularies, often with prior authorization requirements, step-therapy protocols, or preferred status for certain patient populations. The increasing focus on value-based care and outcomes-based contracts by these payers can influence Lyumjev's market penetration.
  • Average Wholesale Price (AWP) and Net Price: The AWP for Lyumjev (e.g., $253.58 for a 3-mL KwikPen) serves as a benchmark, but actual reimbursement is based on negotiated net prices after significant rebates. These net prices are proprietary and not publicly disclosed, but industry estimates suggest rebates can range from 30% to 70% of the list price for insulins.

• International Markets: Lyumjev has also received marketing authorization in other regions, including the European Union (as Lyxumia), Canada, and Japan, each with its own regulatory and reimbursement specificities. These markets often have different pricing controls and reimbursement mechanisms.

What are the Key Strengths and Weaknesses of Lyumjev in the Market?

Understanding the inherent advantages and disadvantages of Lyumjev is crucial for assessing its sustained market position.

• Strengths:

  • Faster Onset of Action: Lyumjev's primary clinical advantage is its rapid absorption, allowing for more flexible mealtime dosing and potentially improved postprandial glucose control. This is supported by clinical trial data comparing its pharmacokinetic profile to other rapid-acting insulins [3].
  • Established Insulin Lispro Platform: It leverages the well-understood efficacy and safety profile of insulin lispro, the active ingredient in Humalog, which has been used for decades.
  • Eli Lilly's Market Expertise: Eli Lilly has a long-standing and deep understanding of the diabetes market, including established relationships with healthcare providers, payers, and patient advocacy groups.
  • Innovative Formulation: The proprietary formulation that enables the rapid action represents a significant R&D achievement.

• Weaknesses:

  • Higher Cost Compared to Older Formulations: Lyumjev generally commands a higher price than older-generation insulins, which can be a barrier for some patients and healthcare systems, particularly in cost-sensitive environments.
  • Competition from Biosimilars (Future Threat): As patent protection wanes, the threat of biosimilar competition will increase, leading to price erosion and market share dilution.
  • Reimbursement Challenges: Navigating complex payer formularies, prior authorization requirements, and step-therapy protocols can limit access for some patients.
  • Lack of Significant Clinical Differentiation in All Scenarios: While faster onset is an advantage, its impact on long-term glycemic control (HbA1c) compared to other rapid-acting insulins may not always be substantial enough to justify a significant price premium for all patients and prescribers.

Key Takeaways

Lyumjev (NDC: 24208-0398) is positioned as an advanced ultra-rapid-acting insulin lispro, differentiated by its faster onset of action. Eli Lilly holds key patents on its specific formulation, providing market exclusivity until the mid-2030s. While current pricing reflects its innovative formulation and R&D investment, significant downward price pressure is anticipated upon biosimilar entry. The drug faces competition from other rapid-acting and ultra-rapid-acting insulins, with payer negotiations and regulatory policies significantly influencing its net reimbursement and market access.

Frequently Asked Questions

1. What is the primary therapeutic advantage of Lyumjev over standard rapid-acting insulins? Lyumjev's primary advantage is its faster onset of action, meaning it begins to lower blood glucose more quickly after injection, allowing for more flexible meal timing.

2. When are the key patents for Lyumjev expected to expire, opening the door for biosimilar competition? Based on current patent filings, significant biosimilar competition is anticipated in the mid-2030s, following the expiration of key formulation and manufacturing process patents.

3. How does the list price of Lyumjev compare to its predecessor, Humalog? At launch, Lyumjev's list price was set to be comparable to or slightly higher than Humalog, reflecting its advanced formulation. Annual list price increases have occurred for both products since then.

4. What factors are most likely to drive down the price of Lyumjev in the long term? The primary drivers of long-term price reduction will be the introduction of biosimilar competitors and increased negotiation leverage by payers due to potential market saturation.

5. Are there specific patient populations for whom Lyumjev's faster onset offers a more pronounced benefit? Patients who struggle with consistent meal timing, those who experience significant postprandial glucose spikes, or individuals with specific insulin delivery device preferences may derive greater benefit from Lyumjev's rapid absorption profile.

Citations

[1] Eli Lilly and Company. (2023). 2022 Annual Report. https://investor.lilly.com/financial-reports/annual-reports [2] U.S. Food and Drug Administration. (2020, June 16). FDA approves Lyumjev (insulin lispro injection) -0073 for U-100 for subcutaneous and intravenous use to improve glycemic control in adults and pediatric patients ages 1 and older with diabetes mellitus. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lyumjev-insulin-lispro-injection-0073-u-100-subcutaneous-and-intravenous-use-improve [3] Rosenstock, J., et al. (2020). Insulin lispro new formulation (LY900014) demonstrates faster pharmacokinetic and pharmacodynamic profiles compared to insulin lispro: results from two randomized trials. Diabetes, Obesity & Metabolism, 22(9), 1661-1670. https://doi.org/10.1111/dom.14077